Literature DB >> 8298269

Opsonization and phagocytosis of Cryptococcus neoformans.

T R Kozel1.   

Abstract

Cryptococcus neoformans is unique among the pathogenic fungi because the yeast is surrounded by an antiphagocytic polysaccharide capsule. Host resistance to cryptococcosis is dependent on natural defense mechanisms that cope with this essential fungal virulence factor. Recent studies in several laboratories indicate that, under appropriate circumstances, the antiphagocytic activity of the capsule can be overcome. A reversal of the antiphagocytic properties of the capsule requires (i) activation of the alternative complement pathway by encapsulated cryptococci, leading to deposition of the opsonic ligand iC3b at the capsular surface, (ii) presence of essential cytokines which up-regulate the efficiency of complement-dependent phagocytosis, and (iii) availability of phagocytic cells whose complement receptors are capable of appropriate up-regulation. Deficiencies in one or more components of the opsonization-phagocyte-cytokine triad may account, in part, for several features of the pathogenesis of cryptococcosis as well as the susceptibility of some immunocompromised patients to cryptococcosis. It may be possible to overcome some deficiencies by passive immunization with anticapsular IgG which takes advantage of phagocyte Fc receptors that are constitutively competent for phagocytosis or by therapeutic use of cytokines that up-regulate complement-dependent phagocytosis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8298269

Source DB:  PubMed          Journal:  Arch Med Res        ISSN: 0188-4409            Impact factor:   2.235


  17 in total

1.  Characterization of a flocculation-like phenotype in Cryptococcus neoformans and its effects on pathogenesis.

Authors:  Li Li; Oscar Zaragoza; Arturo Casadevall; Bettina C Fries
Journal:  Cell Microbiol       Date:  2006-06-07       Impact factor: 3.715

2.  Phagocytosis of Cryptococcus neoformans by, and nonlytic exocytosis from, Acanthamoeba castellanii.

Authors:  Cara J Chrisman; Mauricio Alvarez; Arturo Casadevall
Journal:  Appl Environ Microbiol       Date:  2010-07-30       Impact factor: 4.792

3.  In vitro C3 deposition on Cryptococcus capsule occurs via multiple complement activation pathways.

Authors:  Kileen L Mershon-Shier; Alex Vasuthasawat; Kazue Takahashi; Sherie L Morrison; David O Beenhouwer
Journal:  Mol Immunol       Date:  2011-07-01       Impact factor: 4.407

Review 4.  Dueling in the lung: how Cryptococcus spores race the host for survival.

Authors:  Michael R Botts; Christina M Hull
Journal:  Curr Opin Microbiol       Date:  2010-08       Impact factor: 7.934

5.  Influence of different conditions on kinetics of tumor necrosis factor alpha release by peripheral blood mononuclear cells after stimulation with Cryptococcus neoformans: a possible explanation for different results.

Authors:  W Chaka; A F Verheul; A I Hoepelman
Journal:  Clin Diagn Lab Immunol       Date:  1997-11

6.  Antifungal activity of a human antiglucuronoxylomannan antibody.

Authors:  Z Zhong; L A Pirofski
Journal:  Clin Diagn Lab Immunol       Date:  1998-01

7.  In vivo interaction between alveolar macrophages and Cryptococcus neoformans.

Authors:  K Nessa; N T Gross; C Jarstrand; A Johansson; P Camner
Journal:  Mycopathologia       Date:  1997       Impact factor: 2.574

8.  Antibody action after phagocytosis promotes Cryptococcus neoformans and Cryptococcus gattii macrophage exocytosis with biofilm-like microcolony formation.

Authors:  Mauricio Alvarez; Carolyn Saylor; Arturo Casadevall
Journal:  Cell Microbiol       Date:  2008-04-01       Impact factor: 3.715

9.  Cryptococcus neoformans gene expression during experimental cryptococcal meningitis.

Authors:  B R Steen; S Zuyderduyn; D L Toffaletti; M Marra; S J M Jones; J R Perfect; J Kronstad
Journal:  Eukaryot Cell       Date:  2003-12

10.  Quantitative analysis of phagocytosis and killing of Cryptococcus neoformans by human peripheral blood mononuclear cells by flow cytometry.

Authors:  W Chaka; J Scharringa; A F Verheul; J Verhoef; A G Van Strijp; I M Hoepelman
Journal:  Clin Diagn Lab Immunol       Date:  1995-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.